Given the large and expanding quantity of publicly available sequencing data, it should be possible to extract incidence information for monogenic diseases from allele frequencies, provided one knows which mutations are causal. We tested this idea on a rare, monogenic, lysosomal storage disorder, Sanfilippo Type B (Mucopolysaccharidosis type IIIB).
Mucopolysaccharidosis type IIIB (Sanfilippo Type B), caused by defects in the gene 23 encoding α-N-acetylglucosaminidase (NAGLU), as a case study. We experimentally 24 determined the residual enzyme activity associated with the NAGLU VUS found in 25 ExAC using an in vitro cell-based assay. We found that a large number of NAGLU VUS 26 had enzymatic activity levels low enough to be consistent with known Sanfilippo Type 27 B pathogenic alleles. We showed that such variants make a significant impact on the 28 allele frequency-based estimate of Sanfilippo Type B incidence, bringing it in line with 29 literature reports. 30 We also describe a statistical framework for calculating confidence intervals 31 associated with incidence estimates. This model accounts for differing sample sizes 32 associated with each variant; an important feature when sample sizes can span orders of 33 magnitude from one mutation to the next within the same dataset. We validated our 34 method and found very little deviation between the confidence intervals generated using 35 this framework and what was observed through bootstrapping simulation. 36 Finally, we show that resources such as ExAC present a large enough sample of the 37 population to estimate disease incidence for disorders as rare as Sanfilippo Type B with 38 acceptable error margins. 39 2 Results 40 2.1 The potential contribution of VUS to disease incidence can 41 be significant 42 Figure 1 shows that VUS are likely to contribute significantly to the disease incidence of 43 several lysosomal storage disorders. We compared literature-reported incidence rates 44 with incidence rates calculated using pathogenic variants (Disease causing (DM) 45 variants in HGMD) and loss of function (LOF) variants as defined in Section 4.3 found 46 in ExAC in the Non-Finnish European population (Section 4.5, Methods) . While the 47 combination of previously identified disease mutations from HGMD and high confidence 48 LOF variants made significant contributions to incidence estimates, for almost all 49 disorders we observed that only considering these two categories of variants greatly 50 underestimated disease incidence rates. For example, for Sanfilippo Type B we arrived 51 at an estimated disease incidence of 1 in 1,091,549 using the allele frequencies of HGMD 52 and LOF variants whereas epidemiological data estimate it to be 1 in 321,128 [9] . While 53 there are several factors that might have an impact, the discrepancy between what is 54 reported in the literature, we set out to test the contribution of VUS to the observed 55 discrepancy. In order to understand the contribution of VUS to disease incidence we developed an in 59 vitro cell-based enzymatic activity assay to determine the functional impact of missense 60 VUS in NAGLU. Individual cDNA's for each NAGLU missense mutant were made and 61 transfected in HEK293 cells. NAGLU enzyme activity was measured using a fluorogenic 62 2/21 Allele frequency based incidence estimates of lysosomal storage disorders in the ExAC Non-Finnish Population. Starting with pathogenic (DM) variants in HGMD (orange), incidence was estimated using allele frequencies for each successive class of variant, combining mutations with all previous categories. Loss of function (LoF) variants (blue) were selected as those mutations causing either a splice affecting, stop-gained or frameshift change in the coding sequence which had not been documented in HGMD. Likewise, variants of unknown significance (VUS) were selected as those missense mutations in each gene that had yet to be documented in HGMD. Vertical dashed black lines represent the reported incidence rate of each disorder in the literature for the European region for Sanfilippo Type B [9] , MPS VI [10] , Krabbe [11] , Morquio A (average of the UK, Germany, and the Netherlands) [12] , MPS I [13] , MPS IIIA [9] , and CLN2 (average of Sweden, Norway, Finland, Italy, Portugal, Netherlands, the Czech Republic, and Italy) [2] . assay with the substrate 4-Methylumbelliferyl-N-acetyl-α-D-glucosaminide (see 63 Section 4.2). We tested 164 missense VUS found in ExAC v0.3. We also tested 35 64 deleterious missense mutations reported in HGMD, 17 of which were found in ExAC as 65 well. As shown in Figure 2A , a range of enzymatic activities were observed in these 66 NAGLU VUS. 41 out of 164 assayed VUS displayed enzymatic activities that were less 67 than 15% of wild type (wt) NAGLU activity. 68 We chose 15% wt as a threshold below which mutations are considered deleterious 69 based on the fact that all but three out of 35 tested HGMD annotated pathogenic 70 mutations reduced activity below this level, including three variants associated with 71 attenuated disease (p.S612G, p.E634K, and p.L497V) [14] [15] [16] . The alleles associated 72 with attenuated phenotype showed activity values in the range of 13% to 14% of wt.
73
At this stage it is not clear why three of the putatively pathogenic HGMD mutations, 74 p.A282V, p.P358L, and p.R482W, exhibited greater than 40% wt activity in our assay. 75 We evaluated the relationship between the enzymatic activity and allele frequency of 76 tested variants (Figure 2 Insert B). We found that VUS with greater than 15% wt 77 activity had higher allele frequencies, although this trend was not statistically 78 3/21 significant. These data are consistent with the intuitive notion that high frequency 79 variants are not likely to be associated with rare disease. We found that none of the 80 tested variants with ≤ 15%wt activity had an allele frequency greater than 10 −3 . A dashed line shows the 15%wt activity threshold below which variants are considered to be pathogenic. (Insert B) A box plot (y-axis log scale) of the Non-Finnish European allele frequency of variants with ≤ 15%wt activity (average allele frequency of 3.76 × 10 −5 and those with > 15%wt (average allele frequency of 0.0014). The difference in the average allele frequency between the two groups was not statistically significant (p-value= 0.372, t-test).
Structural characteristics of functional variants 82
Using the publicly available structure of NAGLU (PDB ID 4XWH) we examined the 83 structural characteristics of pathogenic variants (Section 4.4, Figure 3A ). For this 84 analysis we combined variants annotated as "DM" in HGMD with variants exhibiting 85 ≤ 15%wt activity. When considering only mutations within the active-site pocket, 86 almost all mutations (7 of 8) within within this region result in ≤ 15%wt activity. We 87 found that, although most mutations in the active-site profoundly impacted activity, a 88 variant's lack of solvent exposure was more significantly associated with its impact on 89 enzymatic activity than its distance from the active site. The observation has been 90 reported previously [17, 18] We performed several calculations to explore whether current databases represent a 93 large enough sample of the population in order to estimate the incidence of a rare 94 disorder. For this calculation we used the beta distribution to calculate error margins 95 and confidence intervals. We also assumed that only one fully penetrant variant 96 contributes to disease. We found that ExAC, which at the time of data collection had 97 the largest number of exomes among the publicly available databases, contains a The relative solvent exposure in the trimer NAGLU structure of variants with ≤ 15%wt activity and DM variants in HGMD compared to those with > 15%wt activity. ≤ 15%wt activity and DM variants were found to have an average percent solvent exposure of 5.96%. Variants with > 15%wt activity had an average percent solvent exposure of 23.20%. The differences in the average solvent exposure between the two groups was statistically significant at the 5% significance level with a p-value of 1.09 × 10 −12 . (C) The distance to the active site in the NAGLU structure of variants with ≤ 15%wt activity and DM variants in HGMD compared to those with > 15%wt activity. ≤ 15%wt activity and DM variants were found to have an average distance to the active site of 24.03Å . Variants with > 15%wt activity had an average distance to the active site of 27.23Å . The differences in the average distance to the active site between the two groups was statistically significant at the 5% significance level with a p-value of .001.
sufficient number of samples in order to calculate disease incidence with a reasonable 99 margin of error ( Figure 4A ). For the reported disease incidence of 1 in 321,128 for are acceptable for the intended use of the dataset. 106 We estimate that the overall and Non-Finnish European sample sizes of ExAC 107 facilitate the calculation of disease incidence for disease as rare as 1 in 123,285 and 1 in 108 5/21 37,650 respectively with a 95% confidence interval and a 20% margin of error. 109 We also estimated the sample size necessary to achieve a 20% margin of error for a 110 given disease incidence rate at a 95% confidence level (Section 4.11). As shown by 111 Figure 4B , for a disorder as rare as 1 in 300,000, a sample size of roughly 95,000 112 individuals is necessary in order to obtain a 20% margin of error. While this is greater 113 than the size of ExAC, which is made up of roughly 60,000 individuals, it is already 114 exceeded by the number of individuals found in gnomAD.
115
In spite of having higher expected error margins, we used the Non-Finnish European 116 sample in ExAC for all incidence calculations because it represents a more homogenous 117 inter-breeding population than the overall ExAC population. The percent margin of error the lower critical value would represent given a 95% confidence interval when calculating incidence using the same number of chromosomes in ExAC overall and for the Non-Finnish European cohort. The vertical dashed line represents the 1 in 312,128 Sanfilippo Type B incidence rate estimated [9] . (B) The number of individuals which should be sequenced such that the lower critical value will represent a 20% margin of error given a 95% confidence interval for a range of estimated incidence values.
Sanfilippo Type B incidence estimates 119
We derived Sanfilippo Type B incidence estimates using the allele frequencies 120 (Equation (3)) of three types of variants: 1.) HGMD variants 2.) LOF mutations, 121 defined as nonsense, frameshift and splice site mutations not previously documented in 122 HGMD, and 3.) VUS using a range of activity cut-offs ( Figure 5A ).
123
VUS with %wt values ≤ 15% had a profound impact on our estimate of disease 124 incidence, and resulted in estimates that were close to values reported in the literature. 125 Sanfilippo Type B incidence was estimated to be 1 in 355,502 when combining LoF and 126 HGMD mutations with VUS with ≤ 15% wt activity. In contrast, the estimated 127 incidence using only LoF and HGMD variants was 1 in 1,091,549.
128
Furthermore, as shown in Figure 5A , our incidence estimates were relatively 129 insensitive to changes in the threshold used to define deleterious mutations from 10%wt 130 to 15%wt activity. An increase in incidence of only through bootstrapping simulation (Section 4.9). Our framework facilitates the 139 estimation of confidence intervals using either the normal approximation or the beta 140 approximation of the binomial distribution.
141
The confidence intervals we calculated using the beta distribution produced more 142 accurate estimates of the upper and lower bounds of the 95% confidence interval than 143 the normal approximation, although both are in good agreement ( Figure 5B ). Using 144 bootstrapping simulation we observed that 95% of simulated incidence values fell in the 145 range of 1 in 558,306 and 1 in 241,749 for an equal tailed interval (vertical black lines) 146 for our estimate of incidence using VUS with %wt values ≤ 15%. In comparison, using 147 the beta-distribution we estimated that 95% of incidence values would fall in the range 148 of 1 in 566,863 to 1 in 243,753 (vertical dashed orange lines). Using the normal 149 approximation we estimated that 95% of incidence values would fall in the range of 1 in 150 610,093 to 1 in 250,830 (vertical dashed blue lines). 151 2.7 Using in silico predictors to estimate incidence 152 We first evaluated the agreement between in silico predictors of variant functional effect 153 and the results of our activity assay. As shown in Figure 6A -B, PolyPhen and SIFT had 154 roughly similar levels of sensitivity (or recall), but PolyPhen had higher specificity 155 [19, 20] . In spite of this, when we considered the quantitative scores of each predictor we 156 observed that they were more correlated with each other than with our enzymatic Selecting VUS using SIFT and PolyPhen produces reasonable incidence estimates 159 but only after excluding variants with an allele frequency in ExAC greater than 0.1% or 160 for which one or more homozygous individuals were observed. Combining those variants 161 categorized as "deleterious" by SIFT or "probably damaging" by PolyPhen, with LOF 162 and HGMD mutations produced incidence estimate of 1 in 255 Using bootstrapping simulation we observed that 95% of simulated incidence values fell in the range of 1 in 558,306 and 1 in 241,749 for an equal tailed interval (vertical black lines). In comparison, using the beta-distribution we estimated that 95% of incidence values would fall in the range of 1 in 566,863 to 1 in 243,753 (vertical dashed orange lines). Using the normal approximation we estimated that 95% of incidence values would fall in the range of 1 in 610,093 to 1 in 250,830 (vertical dashed blue lines).
≤15%WT Activity approximating the value reported in the literature of 1 in 321,128 [9] . Considering the 188 large number of VUS in ExAC present in other genes (Figure 1 ), we anticipate this 189 finding will be replicated. Thus, VUS should be considered when performing the same 190 For many diseases, though, it might be difficult, expensive, or not feasible to develop 192 an assay in order to test the impact of VUS on the activity of a particular gene product. 193 In this case, one may improve the accuracy of incidence predictions by using in silico 194 methods such as SIFT or PolyPhen. These methods are not reliable enough to predict 195 the pathogenicity of individual variants and therefore should not be used to make 196 clinical interpretations of patient genotypes on their own [30] . However, when the 197 objective is to estimate the contribution to incidence of VUS, incorrect predictions for a 198 small number of variants can be tolerated. We found that using PolyPhen and SIFT, 199 alone or in combination, improved our estimate of disease incidence compared to 200 ignoring the contribution of VUS altogether. These results were only arrived at by 201 applying an allele frequency filter of 0.1% and excluding variants which occurred in the 202 homozygous state in ExAC. Given that information regarding variant impact on 203 NAGLU enzymatic activity was not used to train in silico predictors, our resulting set 204 of 164 screened missense mutations also provide a unique data-set for the development 205 and evaluation of new in silico methods [31] . 206 We recognize that there are complexities to calculating disease incidence due to the 207 consequence of certain allele combinations. Many pathogenic mutations that have high 208 residual activity only cause disease when in the compound heterozygous state with a 209 severe disease variant. This is the case with a very common splice site mutation, Pompe disease. This variant has an allele frequency of 3.5 × 10 −3 in ExAC, but is rarely 212 observed in the homozygous state in Pompe patients [32] . On the other hand, some 213 common severe alleles are only found in the compound heterozygous state with a milder 214 allele. This is the case with the Congenital Disorder of Glycosylation-1a (CDG-1a), 215 caused by deficiencies in Phosphomannomutase 2 (PMM2). There have been no 216 patients reported to be homozygous for the most common severe pathogenic variant 217 10/21 (p.R141H), although the variant has frequently been reported as a compound 218 heterozygote in patients, presumably due to prenatal lethality of the p.R141H/p.R141H 219 genotype [33] . It is also expected that dominant or X-linked severe pathogenic alleles 220 will be depleted in databases of presumably healthy individuals such as ExAC. Such 221 exceptions need to be addressed when attempting to calculate disease incidence. 222 We have provided a theoretical framework in Sections 4.5 and 4.6 for calculating 223 disease incidence and associated error margins. This theoretical framework assumes a 224 randomly mating population at equilibrium [6, 7] . This assumption is certainly not true, 225 which can lead to an underestimate of disease incidence, even when multiple variants 226 contribute to disease [34] . As shown in Table 1 , the reported incidence rate of 227 Sanfilippo Type B in Europe varies by orders of magnitude between countries. Given 228 the exponential growth of population genomics data, allele frequency calculations will 229 become more precise and facilitate the calculation of incidence for rarer disorders.
230
Improved coverage for specific ethno/geographic groups will also enable meaningful 231 calculations for specific populations. Collecting more data, and data that represents the 232 population in a more granular, and unbiased manner will facilitate better disease 233 incidence estimates. In spite of the anticipated growth in genomic data, VUS will still 234 represent a significant challenge for incidence calculations, a challenge that can be 235 addressed through improvements in in silico methods and increases in the throughput 236 of experimental approaches. We selected all NAGLU missense VUS from ExAC (release 0.3.1) for testing [8] . We 240 used HGMD (2016 v1) as a source of disease associated variants [35] . In ExAC there 241 are 207 variants that cause missense substitutions in the protein product NP 000254.2, 242 associated with transcript NM 000263.3. Of these variants 18 failed to pass ExAC's 243 quality filter, resulting in 189 missense variants which we considered. In HGMD there 244 are 90 missense variants associated with NAGLU annotated as being disease causing 245 (assigned the DM or DM? tag). Of these 90 variants 26 were observed in ExAC, 246 although two variants were annotated as failing ExAC's quality filter. The remaining 247 set of 165 missense variants not found in HGMD, which also passed ExAC's quality 248 filter, comprised the final set of missense VUS tested. We were able to successfully assay 249 all but one (V117A) of these mutations for activity (Annotated as "VUS" as their 250 source in S1 Table) . 251 We also tested 38 pathogenic missense variants, 23 of which were found in ExAC as 252 well as 8 nonsense variants, 3 of which had previously been associated with disease.
253
These variants are listed in S1 Table with "HGMD" or "LOF" as their source.
254
SIFT and PolyPhen annotations for these variants were obtained from the ExAC 255 VCF file and were generated using VEP v81. 
Selection of variants for incidence calculation 279
In addition to tested VUS's with low %wt values we utilized previously disease 280 associated variants (annotated as DM in HGMD) observed in ExAC to calculate disease 281 incidence. 23 variants were missense, three were stop gained and one was a splice 282 affecting variant. These variants are listed in S2 Table with "HGMD" annotated as 283 their source. We also found 14 variants categorized loss of function mutations (LOF).
284
Such variants included frame-shift, premature stop gained variants and splice site 285 variants. p.Trp743Ter was excluded from this set given that it exhibited high %wt 286 activity. These variants are listed in S2 Table with "LOF" annotated as their source. Unless noted otherwise, MOE software was used to perform all structural analyses and 289 generate molecular graphics [36] . A human NAGLU crystallographic structure (PDB ID 290 4XWH) was used to identify mutation-site residues involved in N-glycosylation 291 modification, disulfide formation, active-site pocket, and biological assembly. Active-site 292 pocket residues, defined as being located within 4.5 angstroms of a bound active-site 293 ligand, were identified by superimposing the human NAGLU model with a structure of 294 homologous bacterial family 89 glycoside hydrolase (PDB ID 2VCA) complexed with a 295 reaction product, beta-N-acetyl-D-glucosamine (GlcNAc) [37] . Distances from a C-alpha 296 atom of each mutation-site residue to a C-1 atom of the modeled GlcNAc were 297 calculated using a custom MOE svl script. The atomic coordinates of a biological 298 NAGLU trimer generated using COOT were used to identify those residues involved in 299 subunit-subunit interactions at the trimer interface, and to calculate the accessible 300 surface area of a mutation-site residue, expressed as percent surface exposures compared 301 to the ideal surface determined from a Gly-X-Gly peptide [38, 39] . 302 
Estimating incidence 303
We describe methodology for estimating disease incidence with associated confidence 304 intervals. The method we propose can be applied to any monogenic autosomal recessive 305 disorder where multiple, fully penetrant, pathogenic variants contribute to disease.
306
If a single variant v is observed k times in a sample of n /2 individuals from a diploid 307 population then the frequency of that variant, p, is calculated as, 308 p = k n ,
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where n is the number of chromosomes.
309
In the simple, but very unlikely, case where a single variant causes disease the carrier 310 rate is twice the allele frequency of the individual variant. If variants at more than one 311 position in a gene contribute to disease we can calculate the probability at least one 312 disease variant will appear at any position in a single copy of the gene. This is more 313 easily calculated as one minus the probability no disease variant occurs,
where V is the set of variants contributing to disease and q i is one minus p i , the 315 observed frequency of disease variant v i ∈ V . It should be pointed out that for very rare 316 diseases calculating E[P] by taking the sum of all allele frequencies results in values that 317 differ very little from what is arrived at using Equation (2). 318 We then estimated disease incidence (E [I]) in a diploid population, assuming random 319 mating and full penetrance of all variants, as the probability that a disease-causing 320 variant occurs on both the paternal and maternal copy of the gene in an individual,
(
or more simply put as the square of the frequency of copies of the gene with at least one 322 deleterious variant,
This allows us to calculate the expected incidence without enumerating over all 2 |V | − 1 324 possible combinations of alleles. 
where E[P] is defined as above, and Var[P] represents the variance in the frequency of 329 affected copies of the gene. Var[P] was calculated as the variance in the product of |V | 330 random variables [40] , as 331
where Var[p i ] is the variance in the frequency of variant v i ∈ V , and takes the sample 332 size associated with each individual variant into account.
333
For the purposes of this publication we modeled allele frequencies as a binomial 334 distribution; calculating the variance of an individual variant's frequency as,
Both Equation (6) and Equation (5) remain the same when modeling allele frequencies 336 using a hypergeometric distribution and calculating the variance in a single variant's 337 frequency as, 338 13/21
where N represents the overall size of the population being sampled. 
This methodology results in variance estimates that only differ slightly from what is 342 generated using Equation (6), although the behavior of the two equations will be 343 opposite when multiple variants contribute to disease. For example, holding sample size 344 constant, a counter-intuitive observation is that the variance in incidence estimates 345 using Equation (6) will be maximal when only one variant contributes to disease; as the 346 number of variants increases, variance will decrease. Conversely, variance in incidence 347 estimates using Equation (9) will be minimal when only one variant contributes to 348 disease; as the number of variants increases, variance will increase. Variance in observed 349 incidence will also be minimal using Equation (6) 
and,
respectively. 358 We then used Newton's method to find the critical 95% values of the inverse beta 359 cumulative distribution given the α and β parameters. Confidence intervals were also calculated using the normal approximation of the 363 binomial distribution. Very simply, a two-tailed interval can be calculated as,
where z 1− α 2 is the appropriate critical value for the desired percentage of coverage of the 365 normal distribution. We also calculated confidence intervals through bootstrapping simulation. This was 369 carried out by re-estimating each variant's allele frequency, which we will refer to as p , 370 by two methods independently; resampling with replacement and using a binomial 371 random function. Parameters for the binomial random function were set such that the 372 number of trials were equal to the sample size, n, associated with each variant, and the 373 likelihood of success was set to be the frequency, p, of each variant respectively. This 374 method is modifiable so that confidence intervals can be modeled using the 375 hypergeometric distribution, or sampling without replacement. Once each variant's 376 frequency was re-estimated the disease incidence, which we will refer to as I , was 377 re-estimated using Equation (3). This process was carried out over 10 5 iterations, 378 generating a distribution of incidence estimates. Confidence intervals were then 379 estimated by considering the value I for which the defined percentage of observed 380 incidence values from the simulation are greater than or less than.
381
Numerical simulation was carried out in MATLAB. Allele frequencies were 382 re-estimated using the bootstrp or binornd functions, and simulation was carried out 383 using the parallel computing toolbox which relies on the combined multiple recursive 384 random number generator. Code has been provided in the supplemental materials. We also explored calculating confidence intervals using the sum of allele frequencies and 388 the average sample size for all variants. In order to do this we modified Equation (7) to 389 consider the sum of allele frequencies and their average sample size, .
The resulting estimate of Var[P] was then used as input for Equations (5) and (12) . 391 We found that this technique will only be accurate when there is very little variation 392 in the sample size associated with each variant. Using the average sample size it was 393 estimated that 95% of incidence values would fall in the range of 1 in 587,202 to 1 in 394 254,337 for the same data-set as above. While these values are not a drastic departure 395 from what was observed through bootstrapping simulation, there was very little 396 variation in the sample size associated with these variants in the Non-Finnish European 397 population in ExAC (S1 Fig) . In some cases it may be necessary to determine the number of individuals that must be 410 sequenced in order to estimate the incidence of a disorder of a particular rarity within 411 an acceptable margin of error. For the beta distribution this was done by iterating 412 through values of n in order to obtain the appropriate percent margin of error for a 413 given incidence rate. As it may be the case no single value of n will produce an exact 414 desired margin of error value, we chose the n with the closest margin of error. 415 We also provide formulas for such estimates using the normal approximation of the 416 binomial distribution. Given a single variant with allele frequency p contributes to 417 disease, the variance in the expected incidence can be written as, 
Solving Equation (12) for n using Equation (14) one obtains the form,
We use Equation (15) to calculate the number of chromosomes that must be sequenced 420 in order to obtain a given margin of error and confidence interval. Note that, as humans 421 are diploid, n /2 represents the number of individuals necessary to obtain a particular 422 margin of error. represent the distribution of incidence rates observed through bootstrapping simulation. 448 The orange solid line represents the distribution of incidence rates as modeled using the 449 beta distribution. Using bootstrapping simulation we observed that 95% of simulated 450 incidence values fell in the range of 1 in 629,241 to 1 in 226,602 for an equal tailed 451 interval (vertical black lines). Using the beta-distribution we estimated that 95% of 452 incidence values would fall in the range of 1 in 643,633 to 1 in 225,238 (vertical dashed 453 orange lines). Using summed allele frequencies and the average sample size produced a 454 range of 1 in 589,282 to 1 in 253,949 (vertical dashed cyan lines). 455 S1 
